A dual-chamber wireless pacemaker provides reliable performance over three months, bolstering evidence for this new option, according to results from a multi-center international clinical trial co-led by a Weill Cornell Medicine investigator.
An iron-binding drug that is already approved for treatment of other diseases could provide a novel way to attack ovarian tumors, according to a new study led by Weill Cornell Medicine researchers.
Many people enrolled in Medicaid who require psychiatric care have difficulty accessing clinicians in a timely manner despite the higher need in this population, according to a study by researchers at Weill Cornell Medicine.
Two Medicaid policies can interact to increase oncology clinical trial enrollment among Black and Hispanic patients, according to a new study by investigators at Weill Cornell Medicine, the University of Pennsylvania and Medidata AI.
A simple blood test that measures the number of lymphocytes may predict whether people who have relapsed multiple myeloma are going to respond well to CAR-T immunotherapy.
A new preclinical model offers a unique platform for studying the Parkinson’s disease process and suggests a relatively easy method for detecting the disease.
Weill Cornell Medicine has received $4.2 million to study how the immune system in some people infected with HIV can keep the virus under control, which could lead to new therapies.
Researchers at Weill Cornell Medicine have used machine learning to define three subtypes of Parkinson’s disease based on the pace at which the disease progresses.
A new consortium co-led by Weill Cornell Medicine has been awarded a five-year, $31 million grant from the NIH’s National Institute of Allergy and Infectious Diseases to accelerate the development of better treatment regimens for tuberculosis.
